Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Breast Cancer. 2009 Nov;9(4):258-61. doi: 10.3816/CBC.2009.n.044.

TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer.

Author information

1
University of Alberta and Cross Cancer Institute, Edmonton, AB, Canada. john.mackey@cirg.org

Abstract

In this multinational, placebo-controlled, randomized phase III trial, Translational Research In Oncology (TRIO) will define the efficacy and safety of adding a novel antiangiogenic agent, IMC-1121B (ramucirumab), to standard first-line docetaxel chemotherapy for women with HER2-negative metastatic breast cancer. We will evaluate whether the addition of IMC-1121B prolongs progression-free survival and whether its use improves overall survival. Accrual is under way.

PMID:
19933083
DOI:
10.3816/CBC.2009.n.044
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center